Novartis AG (0QLR.L)
| Previous close | 82.85 |
| Open | 81.97 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 81.90 - 82.18 |
| 52-week range | 73.79 - 93.98 |
| Volume | |
| Avg. volume | 603,130 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Novartis raises full-year guidance on Q1 beat, drug sales
Shares of Novartis (NVS) are soaring in Tuesday's pre-market trading session — holding onto steady gains into the market open — after the Swiss pharmaceutical giant reported better-than-expected first-quarter earnings and raised its full-year guidance. The robust financial performance was driven primarily by strong sales of the company's innovative heart failure and psoriasis treatment drugs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
- Yahoo Finance UK
Trending tickers: Tesla, ABF, Novartis, Taylor Wimpey, JD Sports
The latest investor updates on stocks that are trending on Tuesday.
- Yahoo Finance
Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.
Antitrust lawsuits have declined since the pandemic despite a high-profile push by Washington to limit the concentration of power in key industries.
